

Cynomolgus IL-23 alpha & Mouse IL-12 beta Heterodimer Protein (HEK293, His)

Cat. No.:	HY-P77703
Synonyms:	IL23 alpha; IL12 beta; IL23 alpha&IL12 beta
Species:	Cynomolgus
Source:	HEK293
Accession:	A0A2K5TLV4 (V22-P189)&P43432 (M23-S335)
Gene ID:	102128555&16160
Molecular Weight:	22 (Cynomolgus IL23 alpha)&40-50 (Mouse IL12 beta) kDa

PROPERTIES

AA Sequence

```

V P G G S S P A W A   Q C Q Q L S Q K L C   T L A W S A H P L V   G H M D L R E E G D
E E T T N D V P H I   Q C G D G C D P Q G   L R D N S Q F C L Q   R I R Q G L I F Y E
K L L G S D I F T G   E P S L L P D S P V   G Q L H A S L L G L   S Q L L Q P E G H H
W E T Q Q I P S P S   P S Q P W Q R L L L   R F K I L R S L Q A   F V A V A A R V F A
H G A A T L S P & M   W E L E K D V Y V V   E V D W T P D A P G   E T V N L T C D T P
E E D D I T W T S D   Q R H G V I G S G K   T L T I T V K E F L   D A G Q Y T C H K G
G E T L S H S H L L   L H K K E N G I W S   T E I L K N F K N K   T F L K C E A P N Y
S G R F T C S W L V   Q R N M D L K F N I   K S S S S S P D S R   A V T C G M A S L S
A E K V T L D Q R D   Y E K Y S V S C Q E   D V T C P T A E E T   L P I E L A L E A R
Q Q N K Y E N Y S T   S F F I R D I I K P   D P P K N L Q M K P   L K N S Q V E V S W
E Y P D S W S T P H   S Y F S L K F F V R   I Q R K K E K M K E   T E E G C N Q K G A
F L V E K T S T E V   Q C K G G N V C V Q   A Q D R Y Y N S S C   S K W A C V P C R V
R S
  
```

Biological Activity Cynomolgus IL-23R, His Tag immobilized on CM5 Chip can bind Cynomolgus IL-23 alpha&Mouse IL-12 beta, His Tag with an affinity constant of 2.36 nM as determined in SPR assay (Biacore T200).

Appearance Lyophilized powder.

Formulation Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4. Normally 8% trehalose is added as protectant before lyophilization.

Endotoxin Level <1 EU/µg, determined by LAL method.

Reconstitution It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH₂O.

Storage & Stability Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

IL-23 alpha and IL-12 beta, also known as IL23p19 and IL12p40, respectively, and composing IL-23 in a heterodimerization manner, exerts proinflammatory effects and promotes angiogenesis^{[1][5]}.

IL-23 belongs to the IL-12 cytokine family together with IL-12 p35/p40, IL-27 EBI3/p28 and IL-35 EBI3/p35, and is produced by various immune cells such as dendritic cells and macrophages upon Toll-like receptor signaling in tissues^[3].

IL-23 has a preference expression on memory CD4(+) T cells, and activates the Jak-Stat signaling cascade. IL-23 leads to IL-23 receptor phosphorylation and forms a docking site to trigger phosphorylation signal of STAT3 and STAT4^[1].

IL-23 is a key factor perpetuating Th17 cell activation and cytokine production by binding IL-23 receptor to produce Th17 cytokines such as IL17 A, IL-17 F and IL-22^[2].

IL-23 also acts function on natural killer cells, results interferon- γ secretion increasing and enhances antibody-dependent cellular cytotoxicity^[4].

The sequence of amino acids in IL-23 alpha proteins of cynomolgus shows high similarity with human (97.88%) and is very different from mouse (74.6%) and rat (79.37%)

IL-23 facilitates development of inflammation in numerous other models of immune pathology where IL-12 had previously been implicated, including models of arthritis, intestinal inflammation, and psoriasis^{[6][7][8]}.

REFERENCES

- [1]. Oppmann B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. *Immunity*. 2000 Nov;13(5):715-25.
- [2]. Parham C, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. *J Immunol*. 2002 Jun 1;168(11):5699-708.
- [3]. Neurath MF. IL-23 in inflammatory bowel diseases and colon cancer. *Cytokine Growth Factor Rev*. 2019 Feb;45:1-8.
- [4]. Teng MW, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. *Nat Med*. 2015 Jul;21(7):719-29.
- [5]. Li Y, et al. Regulation of Memory T Cells by Interleukin-23. *Int Arch Allergy Immunol*. 2016;169(3):157-62.
- [6]. Langowski JL, et al. IL-23 promotes tumour incidence and growth. *Nature*. 2006 Jul 27;442(7101):461-5.
- [7]. Murphy CA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. *J Exp Med*. 2003 Dec 15;198(12):1951-7.
- [8]. Yen D, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. *J Clin Invest*. 2006 May;116(5):1310-6.
- [9]. Chan JR, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. *J Exp Med*. 2006 Nov 27;203(12):2577-87.
- [10]. Yago T, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. *Arthritis Res Ther*. 2007;9(5):R96.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA